Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Recent Progress and Emerging Trends. [PDF]
Curr OncolCatacalos-Goad C +2 more
europepmc +1 more source
pH-responsive virus-drug conjugates for targeted PD-L1 silencing and enhanced cancer immunotherapy. [PDF]
J NanobiotechnologyTseng SJ +4 more
europepmc +1 more source
Bridging mechanism and clinic: unlocking the full potential of oncolytic virus-based immunotherapy. [PDF]
Mol CancerHua X +6 more
europepmc +1 more source
Oncolytic viruses: Revolutionising the fight against tumours. [PDF]
Clin Transl MedZhao Z, Shen Y, Liang T.
europepmc +1 more source
Correction: Single-cell analysis of oncolytic virotherapy in adult T-cell leukemia/lymphoma. [PDF]
J Immunother Cancereuropepmc +1 more source
Oncolytic virus therapy for hepatocellular carcinoma: A bibliometric analysis of research landscapes, hotspots, and clinical transformation trends from 2000 to mid-2025. [PDF]
Hum Vaccin ImmunotherYu F, Yin S, Zhu J, Sun K.
europepmc +1 more source
The α-Gal Epitope (Galα1-3Galβ1-4GlcNAc) as Therapeutic Agent in Cancer Immunotherapy, Vaccine Effectiveness Amplification and Injured Tissue Regeneration. [PDF]
Int J Mol SciGalili U.
europepmc +1 more source
CAR-T Cell Therapy in Glioblastoma: Overcoming Immunological Barriers and Advancing Clinical Translation. [PDF]
Cancer Manag ResPourmasoumi P +4 more
europepmc +1 more source
Dual-chemokine-armed oncolytic Senecavirus A co-recruits cDC1 and CXCR3<sup>+</sup> T cells to convert 'cold' melanoma and drive durable regression. [PDF]
J Immunother CancerLi W +9 more
europepmc +1 more source
Harnessing oncolytic viruses to overcome immunosuppression in breast cancer: from mechanisms to clinical translation. [PDF]
Front ImmunolXianshu K +6 more
europepmc +1 more source